University of Arizona Medical Center - Tucson
Welcome,         Profile    Billing    Logout  
 8 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nath, Rajneesh
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting
3
450
US
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Delta-Fly Pharma, Inc.
Leukemia, Myeloid, Acute
12/22
12/22
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Checkmark Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Checkmark From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Hourglass Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL
More
Recruiting
1/2
320
Canada, US
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Juno Therapeutics, a Subsidiary of Celgene
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
11/27
11/27
NCT04649112: Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies

Completed
1
13
US
PBCAR19B, Allogeneic Anti-CD19 CAR T cells
Precision BioSciences, Inc.
CD19 Expressing Malignancies, Hematologic Malignancy
12/22
09/23
PBCAR0191-01, NCT03666000: Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL

Recruiting
1
129
US, RoW
Azer-cel, Allogeneic Anti-CD19 CAR T cells, PBCAR0191, Fludarabine, Cyclophosphamide, IL-2, Bendamustine
Imugene Limited
Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
06/25
06/27
FRIDA, NCT05546580: Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Checkmark First-patient-in of FRIDA trial in combination with gilteritinib for r/r AML
Nov 2022 - Nov 2022: First-patient-in of FRIDA trial in combination with gilteritinib for r/r AML
Recruiting
1
50
US
Iadademstat, ORY-1001, RO7051790, Gilteritinib Oral Tablet, XOSPATA®
Oryzon Genomics S.A.
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
11/25
11/25
SER-155-001, NCT04995653: A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT

Completed
1
60
US
Vancomycin Pre-Treatment, Vancomycin Placebo, SER-155, SER-155 Placebo
Seres Therapeutics, Inc., Memorial Sloan Kettering Cancer Center
Allogeneic Hematopoietic Stem Cell Transplantation
07/24
07/24
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
Katsanis, Emmanuel
Allo-X, NCT06643221: Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

Recruiting
1
100
US
Exercise, Isoproterenol, Placebo, Bisoprolol Fumarate Tablet 10 mg, Nadolol (1 x 80 mg) Tablets (Invamed, Inc), Carvedilol 50 mg, Roflumilast 500 Mcg Oral Tablet
University of Arizona, National Cancer Institute (NCI)
Leukemia, Hematopoetic Stem Cell Transplantation, Donor Lymphocyte Infusion, CAR T-Cell Therapy, Lymphoma, Cell Therapy
12/28
12/28
NCT02996773: Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine

Active, not recruiting
1
50
US
Bendamustine, BEN, Cyclophosphamide, CY
University of Arizona
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Lymphoma,Non-Hodgkin, Lymphoma, Hodgkin, Lymphoma, Follicular, Marginal Zone Lymphoma, Large Cell Lymphoma, Mantle-Cell Lymphoma, Gray Zone Lymphoma, Burkitt Lymphoma, High Risk Undifferentiated Acute Leukemia
08/25
08/25
NCT05597228: Tech-TYA: eHealth Platform to Deliver Group Intervention for YA Cancer Survivors

Completed
N/A
7
US
Cognitive-Behavioral Stress Management and Health Education
University of Arizona
Cancer
04/23
04/23
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available
N/A
Canada, US, RoW
CTL019, tisagenlecleucel, Kymriah
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
 
 
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41

Download Options